Palvella Therapeutics Announces Pricing of Upsized Public Offering

Group 1 - Palvella Therapeutics, Inc. announced the pricing of its upsized public offering of 1,600,000 shares at $125.00 per share, with expected gross proceeds of $200 million [1] - The offering includes a 30-day option for underwriters to purchase an additional 240,000 shares [1] - The offering is expected to close on or about February 27, 2026, subject to customary closing conditions [1] Group 2 - The net proceeds from the offering will be used to support the development of programs including QTORIN rapamycin and QTORIN pitavastatin, as well as for working capital and general corporate purposes [3] - The offering is made pursuant to a shelf registration statement declared effective by the SEC on January 29, 2026 [4] Group 3 - Palvella is focused on developing therapies for serious, rare skin diseases and vascular malformations, with a pipeline based on its patented QTORIN™ platform [6] - The lead product candidate, QTORIN™ rapamycin, is being developed for microcystic lymphatic malformations and other conditions, while QTORIN™ pitavastatin is for the treatment of disseminated superficial actinic porokeratosis [6][7]